DrugDashboards

Posluma

flotufolastat F-18 · FLOTUFOLASTAT F-18 158 mCi/mL · Injection · Intravenous · Blue Earth Diagnostics

NDC 69932-0002-50 · 25 mL in 1 VIAL, MULTI-DOSE · NDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA216023
TE code
Approval date
May 25, 2023
Patents / exclusivity
6 patents, 1 exclusivities
TypeNumber / codeExpires
exclusivityNCEMay 25, 2028
patent12036290Nov 27, 2041
patent12427207Nov 27, 2041
patent12357711Nov 22, 2038
patent11413360Nov 22, 2038
patent12377176Nov 22, 2038
patent12390540Aug 23, 2038

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of flotufolastat F-18 (Injection)

LabelerStrengthFirst seenLast seen
Blue Earth DiagnosticsFLOTUFOLASTAT F-18 158 mCi/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Posluma — NDC 69932-0002-50," retrieved September 3, 2026, https://drugdashboards.com/drug/69932000250.

Free to cite with attribution — see how the data is put together.